It is with great sadness that The John Douglas French Alzheimer's Foundation announces the passing of its former President, Michael M. Minchin, Jr. on March 22, 2016. For nearly two decades, Mike has been instrumental in the success of The John Douglas French Alzheimer's Foundation. He cared deeply about the foundation and its mission, giving it his full commitment, energy, and passion.
Since 1983, The John Douglas French Alzheimer's Foundation has funded some of the most innovative Alzheimer's research. Our research focuses on novel areas—generally not being explored by other organizations—in order to gain new insights and a better understanding of Alzheimer's disease at its most fundamental level. Research of this type is an essential step in identifying high-value pathways to a cure.
First Alzheimer's Drug Shown in Early Stage Clinical Trial to Remove Beta Amyloid Plaque and Slow Cognitive Decline.
As of the end of last year (2014), more than two-hundred forty-four Alzheimer's drug compounds have been tested, with failure rate that exceeds 99 percent.
But a new treatment is showing real promise in early stage clinical trials.
New diet shown to significantly reduce the risk for Alzheimer's.
A new study, reported in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, finds that adhering to a new diet, developed by researchers at Rush University Medical Center in Chicago, can significantly lower the risk for developing Alzheimers.
New studies suggest women's brains are more vulnerable to Alzheimer's than men’s.
Two-thirds of all individuals in the US diagnosed with Alzheimer’s are women — a circumstance long explained by scientists by the fact that women live longer than men.
Two new studies presented at the 2015 Alzheimer's Association International Conference (AAIC) in Washington, DC suggest there may be more to the story.